MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine or as TMA2-4-EtO, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to TMA-2. https://www.erowid.org/library/books_online/pihkal/pihkal122.shtml It is the analogue of TMA-2 in which the methoxy group at the 4 position has been replaced with an ethoxy group. The drug was first described in the scientific literature by Alexander Shulgin by 1968.
Use and effects In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MEM's dose as 20 to 50mg orally and its duration as 10 to 14hours. Its onset is rapid at 10 to 30minutes and peak effects occur at about 1.5hours. The first noticeable decrease in effects occurred at 6hours and the decline is slow. The effects of MEM have been reported to include visual phenomena, color and contrast enhancement, introspection and fantasy, lucidity or clarity, insights, good feelings or pleasantness, euphoria, lots of energy, need to keep moving and hard to stay still, eroticism, and tactile sensitivity. It was described as being "intense yet serene". Other effects of MEM included physical discomfort, queasiness, tremors, bodily sensitivity, and difficulty sleeping. MEM has sometimes been combined with MDMA for the purpose of lessening MEM's physical side effects.
Interactions
Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A >10,000 5-HT1B >10,000 5-HT1D >10,000 5-HT1E >10,000 5-HT1F 5-HT2A 73.0–3,948 (Ki)47.5–295 ()88–105% () 5-HT2B 64.5–763 (Ki)437–557 ()70–96% () 5-HT2C 124–>10,000 (Ki)29.9–248 ()98–129% () 5-HT3 >10,000 5-HT4 5-HT5A >10,000 5-HT6 >10,000 5-HT7 7,156 α1A, α1B >10,000 α1D α2A–α2C >10,000 β1, β2 >10,000 β3 D1–D5 >10,000 H1–H4 >10,000 M1–M5 >10,000 I1 >10,000 σ1 5,077 σ2 >10,000 >10,000 (Ki) >10,000 (Ki) >10,000 (Ki) Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:
MEM is a serotonergic psychedelic and acts as a selective serotonin 5-HT2 receptor agonist. It is specifically a full agonist of the serotonin 5-HT2A and 5-HT2C receptors and to a lesser extent is a partial to full agonist of the serotonin 5-HT2B receptor. The psychedelic effects of MEM are thought to be mediated by serotonin 5-HT2A receptor activation.
Chemistry MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine, is a phenethylamine, amphetamine, and DOx derivative. It is the analogue and derivative of 2,4,5-trimethoxyamphetamine (TMA-2) in which a 4-ethoxy group is present instead of a 4-methoxy group.
Synthesis The chemical synthesis of MEM has been described.
Derivatives A variety of derivatives of MEM have been developed and studied, not only by Alexander Shulgin but also by for instance Daniel Trachsel and colleagues. These include MPM, MIPM, MALM, MBM, MAM, MMALM, MFEM, MDFEM, and MTFEM, among others.
History MEM was first synthesized by Alexander Shulgin. It was first described by him in the scientific literature by 1968. Subsequently, Shulgin described MEM in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Society and culture Legal status Canada MEM is a controlled substance in Canada.
United States MEM is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
See also DOx (psychedelics) TWEETIO § DOx compounds EMM and MME
References
External links MEM - Isomer Design MEM - PiHKAL - Erowid MEM - PiHKAL - Isomer Design The Small & Handy MEM Thread - Bluelight